Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model

[1]  W. H. Pearse.  American College of Obstetricians and Gynecologists , 2020, Definitions.

[2]  Vittorio Krogh,et al.  Circulating anti‐Müllerian hormone and breast cancer risk: A study in ten prospective cohorts , 2018, International journal of cancer.

[3]  A. Tjønneland,et al.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women. , 2017, Fertility and sterility.

[4]  A. Fournier,et al.  Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort , 2017, Clinical Cancer Research.

[5]  M. Eijkemans,et al.  Back to the basics of ovarian aging: a population-based study on longitudinal anti-Müllerian hormone decline , 2016, BMC Medicine.

[6]  B. Rosner,et al.  Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[7]  T. Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[8]  G. Giles,et al.  Breast Cancer Risk Prediction Using Clinical Models and 77 Independent Risk-Associated SNPs for Women Aged Under 50 Years: Australian Breast Cancer Family Registry , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[9]  C. Kooperberg,et al.  SNPs and breast cancer risk prediction for African American and Hispanic women , 2015, Breast Cancer Research and Treatment.

[10]  J. Lortet-Tieulent,et al.  Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society. , 2015, JAMA.

[11]  A. Pinborg,et al.  Ovarian reserve assessment in users of oral contraception seeking fertility advice on their reproductive lifespan. , 2015, Human reproduction.

[12]  Charmaine Pei Ling Lee,et al.  Mammographic Breast Density and Common Genetic Variants in Breast Cancer Risk Prediction , 2015, PloS one.

[13]  M. Gail.  Twenty-five years of breast cancer risk models and their applications. , 2015, Journal of the National Cancer Institute.

[14]  D. Baird,et al.  Anti-Müllerian Hormone Concentrations in Premenopausal Women and Breast Cancer Risk , 2015, Cancer Prevention Research.

[15]  Stefan Michiels,et al.  A comparison between different prediction models for invasive breast cancer occurrence in the French E3N cohort , 2015, Breast Cancer Research and Treatment.

[16]  M. García-Closas,et al.  Combined associations of genetic and environmental risk factors: implications for prevention of breast cancer. , 2014, Journal of the National Cancer Institute.

[17]  Peter Kraft,et al.  Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Clavel-Chapelon,et al.  Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status—Results from the EPIC cohort , 2014, International journal of cancer.

[19]  A. Ashworth,et al.  Combined effects of endogenous sex hormone levels and mammographic density on postmenopausal breast cancer risk: results from the Breakthrough Generations Study , 2014, British Journal of Cancer.

[20]  F. Berrino,et al.  Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. , 2013, The Lancet. Oncology.

[21]  J. Cuzick,et al.  Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  P. Hartge,et al.  Risk Prediction for Breast, Endometrial, and Ovarian Cancer in White Women Aged 50 y or Older: Derivation and Validation from Population-Based Cohort Studies , 2013, PLoS medicine.

[23]  G. Giles,et al.  Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model , 2013, Breast Cancer Research and Treatment.

[24]  Anne Marie McCarthy,et al.  Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American women , 2013, Breast Cancer Research and Treatment.

[25]  W. Willett,et al.  Premenopausal endogenous steroid hormones and breast cancer risk: results from the Nurses' Health Study II , 2013, Breast Cancer Research.

[26]  Xuehong Zhang,et al.  Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up , 2013, Breast Cancer Research and Treatment.

[27]  Peter Kraft,et al.  Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status , 2012, Journal of Medical Genetics.

[28]  E. Papaleo,et al.  Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history. , 2012, European journal of obstetrics, gynecology, and reproductive biology.

[29]  Patrik Magnusson,et al.  American Journal of Epidemiology Practice of Epidemiology Risk Prediction Measures for Case-cohort and Nested Case-control Designs: an Application to Cardiovascular Disease , 2022 .

[30]  L. Hauk.  American College of Obstetricians and Gynecologists Updates Breast Cancer Screening Guidelines , 2012 .

[31]  Ammarin Thakkinstian,et al.  Risk prediction models of breast cancer: a systematic review of model performances , 2012, Breast Cancer Research and Treatment.

[32]  Mengling Liu,et al.  Premenopausal serum androgens and breast cancer risk: a nested case-control study , 2012, Breast Cancer Research.

[33]  Jianjun Liu,et al.  Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement , 2011, Breast Cancer Research.

[34]  L. Brinton,et al.  Serum antimüllerian hormone in healthy premenopausal women. , 2011, Fertility and sterility.

[35]  Mitchell H Gail,et al.  Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. , 2011, Journal of the National Cancer Institute.

[36]  J. Manson,et al.  Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. , 2011, Journal of the National Cancer Institute.

[37]  Practice bulletin no. 122: Breast cancer screening. , 2011, Obstetrics and gynecology.

[38]  L. Brinton,et al.  Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk , 2010, Breast Cancer Research.

[39]  David A. Hinds,et al.  Assessment of Clinical Validity of a Breast Cancer Risk Model Combining Genetic and Clinical Information , 2010, Journal of the National Cancer Institute.

[40]  L. Brinton,et al.  Assay reproducibility and within-person variation of Müllerian inhibiting substance. , 2010, Fertility and sterility.

[41]  P. Hartge,et al.  Effect of changing breast cancer incidence rates on the calibration of the Gail model. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Thun,et al.  Performance of Common Genetic Variants in Breast-cancer Risk Models , 2022 .

[43]  D. Saslow,et al.  Cancer Screening in the United States, 2010: A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening , 2010, CA: a cancer journal for clinicians.

[44]  D. English,et al.  Circulating Steroid Hormone Levels and Risk of Breast Cancer for Postmenopausal Women , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[45]  Timothy J Wilt,et al.  Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement. , 2009, Annals of internal medicine.

[46]  L. Brinton,et al.  Prospective Case–Control Study of Serum Müllerian Inhibiting Substance and Breast Cancer Risk , 2009, Journal of the National Cancer Institute.

[47]  D. Schopper,et al.  How effective are breast cancer screening programmes by mammography? Review of the current evidence. , 2009, European journal of cancer.

[48]  J. Cuzick,et al.  American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  F. Berrino,et al.  Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort , 2009, Cancer Epidemiology Biomarkers & Prevention.

[50]  R. Vierkant,et al.  Assessment of the accuracy of the Gail model in women with atypical hyperplasia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Gail.  Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. , 2008, Journal of the National Cancer Institute.

[52]  Karla Kerlikowske,et al.  Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model , 2008, Annals of Internal Medicine.

[53]  Melissa Bondy,et al.  Projecting individualized absolute invasive breast cancer risk in African American women. , 2007, Journal of the National Cancer Institute.

[54]  G. Anderson,et al.  Predicting risk of breast cancer in postmenopausal women by hormone receptor status. , 2007, Journal of the National Cancer Institute.

[55]  C. Klabunde,et al.  Evaluating Population-Based Screening Mammography Programs Internationally. , 2007, Seminars in breast disease.

[56]  Stefano Calza,et al.  Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. , 2006, Journal of the National Cancer Institute.

[57]  D. Spiegelman,et al.  Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. , 2006, Journal of the National Cancer Institute.

[58]  S. Reis,et al.  Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2006 .

[59]  Karla Kerlikowske,et al.  Prospective breast cancer risk prediction model for women undergoing screening mammography. , 2006, Journal of the National Cancer Institute.

[60]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.

[61]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[62]  D. Spiegelman,et al.  Reproducibility of Plasma Steroid Hormones, Prolactin, and Insulin-like Growth Factor Levels among Premenopausal Women over a 2- to 3-Year Period , 2006, Cancer Epidemiology Biomarkers & Prevention.

[63]  J. Chang-Claude,et al.  Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. , 2005, Endocrine-related cancer.

[64]  S. Cummings,et al.  Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population , 2005, Breast Cancer Research and Treatment.

[65]  J. Chang-Claude,et al.  Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC) , 2005 .

[66]  J. Habbema,et al.  Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. , 2005, Fertility and sterility.

[67]  F. Berrino,et al.  Endogenous sex hormones and subsequent breast cancer in premenopausal women , 2004, International journal of cancer.

[68]  F. Berrino,et al.  Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: a cross-sectional study in healthy women. , 2004, European journal of endocrinology.

[69]  R. Shore,et al.  Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study , 2004, British Journal of Cancer.

[70]  G. Berglund,et al.  Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden) , 2003, Cancer Causes & Control.

[71]  Sowmya R. Rao,et al.  Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. , 2003, Journal of the National Cancer Institute.

[72]  A. Oshima,et al.  Estimation of individualized probabilities of developing breast cancer for Japanese women , 2003, Breast cancer.

[73]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[74]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[75]  K. Hughes,et al.  The Effectiveness of the Gail Model in Estimating Risk for Development of Breast Cancer in Women Under 40 Years of Age , 2001, The breast journal.

[76]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[77]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[78]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[79]  Sven Ove Samuelsen,et al.  A psudolikelihood approach to analysis of nested case-control studies , 1997 .

[80]  M. Dowsett,et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of Guernsey. , 1997, British Journal of Cancer.

[81]  M. Dowsett,et al.  A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of Guernsey. , 1997, British Journal of Cancer.

[82]  C. D. Atkins.  Re: Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.

[83]  G. Colditz,et al.  COMMENT ON : VALIDATION OF THE GAIL ET AL. MODEL FOR PREDICTING INDIVIDUALBREAST CANCER RISK. AUTHORS' REPLY , 1994 .

[84]  Re: Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.

[85]  D P Byar,et al.  Estimating the population attributable risk for multiple risk factors using case-control data. , 1985, American journal of epidemiology.